OMEROS CORP Finance Lease, Right-of-Use Asset, after Accumulated Amortization
OMEROS CORP (OMER) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $1.29 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-03-31
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.29M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.02M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.22M.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $945.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $1.29M 10-K · filed 2026-03-31 |
| 2024-12-31 | $2.02M 10-K · filed 2026-03-31 |
| 2023-12-31 | $1.22M 10-K · filed 2025-03-31 |
| 2022-12-31 | $945.00K 10-K · filed 2023-03-13 |
| 2021-12-31 | $1.01M 10-K · filed 2023-03-13 |
| 2020-12-31 | $1.82M 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.15M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $2.31M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.64M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.97M 10-K · filed 2021-03-01 |
| 2019-09-30 | $2.77M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.11M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $3.41M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |